BioLine RX Stock

BioLine RX Revenue

Delisted

The The revenue of BioLine RX (BLRX.TA) as of Jul 17, 2026 is 28.94 M USD. In the previous year, The revenue was 4.80 M USD — a change of 502.92% (higher).

Revenue

28.94 MUSD

YoY

502.92%

Last updated:

In 2026, BioLine RX's sales reached 28.94 M USD, a 502.92% difference from the 4.80 M USD sales recorded in the previous year.

Revenue has compounded at 3.9% per year over the past 15 years to 28.94 M USD.

The BioLine RX Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

REVENUE (M USD)
GROSS MARGIN (%)
Date
REVENUE (M USD)
GROSS MARGIN (%)
Jan 1, 2017
0.00 base
0.00 base
Jan 1, 2018
0.00 base
0.00 base
Jan 1, 2019
0.00 base
0.00 base
Jan 1, 2020
0.00 base
0.00 base
Jan 1, 2021
0.00 base
0.00 base
Jan 1, 2022
0.00 base
0.00 base
Jan 1, 2023
4.80 base
23.08 base
Jan 1, 2024
28.94 base
67.99 base
YEARREVENUE (M USD)GROSS MARGIN (%)
2024 28.9467.99
2023 4.8023.08
2022 --
2021 --
2020 --
2019 --
2018 --
2017 --
2016 --
2015 --
2014 --
2013 --
2012 --
2011 --
2010 30.3377.38
2009 16.3064.60
2008 --
2007 --
2006 --
2005 --
Access this data via the Eulerpool API

BioLine RX Revenue

BioLine RX Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2017
0.00 USD
-25.24 M USD
-24.35 M USD
Jan 1, 2018
0.00 USD
-25.61 M USD
-22.96 M USD
Jan 1, 2019
0.00 USD
-28.11 M USD
-25.45 M USD
Jan 1, 2020
0.00 USD
-22.93 M USD
-30.02 M USD
Jan 1, 2021
0.00 USD
-24.78 M USD
-27.05 M USD
Jan 1, 2022
0.00 USD
-29.16 M USD
-24.95 M USD
Jan 1, 2023
4.80 M USD
-42.99 M USD
-60.61 M USD
Jan 1, 2024
28.94 M USD
-19.40 M USD
-9.22 M USD

BioLine RX Margins

BioLine RX stock margins

The BioLine RX margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioLine RX. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioLine RX.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
67.99 %
- %
- %
Jan 1, 2018
67.99 %
- %
- %
Jan 1, 2019
67.99 %
- %
- %
Jan 1, 2020
67.99 %
- %
- %
Jan 1, 2021
67.99 %
- %
- %
Jan 1, 2022
67.99 %
- %
- %
Jan 1, 2023
23.08 %
-895.65 %
-1,262.79 %
Jan 1, 2024
67.99 %
-67.03 %
-31.86 %

BioLine RX Stock analysis

What does BioLine RX do? BioLine RX Ltd is a global biopharmaceutical company specializing in the development of novel therapies for cancer and other serious diseases. The company is headquartered in Israel and has offices in the United States and Europe. BioLine RX is one of the most popular companies on Eulerpool.

Revenue Details

Understanding BioLine RX's Sales Figures

The sales figures of BioLine RX originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing BioLine RX’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize BioLine RX's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in BioLine RX’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about BioLine RX stock

The revenue of BioLine RX is 28.94 M USD in 2026.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — BioLine RX

All Key Metrics — BioLine RX